Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Molecular Profiles’ Innovative Drug Development Services Win Queen’s Award for Enterprise 2011

Abstract:
Molecular Profiles, a leading pharmaceutical development service provider, today announced that it has been awarded a Queen's Award for Enterprise 2011 in the Innovation category for its nanoPASS™ (nanoscale Predictive Analytical Screening Solution) service platform. This novel analytical approach improves the development of new pharmaceuticals by exploiting the latest advances in nanotechnology to yield key analytical data from minute quantities of potential drug candidates and then predicting those candidates that are most likely to make it to market. It helps customers to substantially reduce R&D and production costs and enables earlier introduction of new medicines to market benefiting both industry and patients.

Molecular Profiles’ Innovative Drug Development Services Win Queen’s Award for Enterprise 2011

Nottingham, UK | Posted on April 21st, 2011

The Queen's Award for Enterprise is the most prestigious and widely recognised accolade for UK industry. The Innovation category recognises companies that have demonstrated spectacular commercial success through innovative products or services. Following a 2007 Queen's Award for Continuous Innovation and Development, the 2011 award honours Molecular Profiles for the creation of cutting-edge development services that significantly improve and speed-up the introduction of new drugs.

The nanoPASS service platform uses new analytical approaches to yield key physical and chemical data from minute quantities of many possible drug candidates. Critically this allows clients to predict the potential of each candidate to be manufactured into a medicine at an earlier time than has previously been possible. Prior to this unique solution, prediction analyses were made through iterative research and bulk testing of drug substance. These methods can be expensive and require large amounts of drug substance which is usually not available at early development stages. NanoPASS delivers predictions faster and at an earlier stage.

Molecular Profiles offers a complete portfolio of drug development services including formulation development, preformulation, polymorph screening, salt selection, analytical services and clinical trial manufacturing for up to phase IIa. This extensive range of solutions all under one roof decreases the need to perform a technical transfer of work to other companies and therefore lessens the risk to the customer's research.

Nikin Patel, PhD MRPharmS, CEO of Molecular Profiles, commented, "We are very pleased that our innovative approach has been recognised by the Queen's Award for Enterprise 2011. This great success could not be achieved without the expertise of our team. This accolade recognises their commitment and ability to solve some of the toughest drug development issues."

####

About Molecular Profiles
Molecular Profiles was founded in 1997 by a group of pharmaceutical scientists specialising in advanced characterisation of pharmaceutical and biological materials. Since then, the company has achieved a unique global position in pharmaceutical R&D and developed a wide portfolio of clients including major pharmaceutical companies. With a highly expert scientific team and complete range of services from formulation development to clinical trial manufacturing, Molecular Profiles is ideally placed to offer its clients a range of targeted solutions and help them to overcome the most challenging issues in drug development.

For more information, please click here

Contacts:
Molecular Profiles

Dr. Nikin Patel
+44 115 8718888

For further press information please contact:
Fiona Robinson
The Scott Partnership
1 Whiteside, Station Road
Holmes Chapel, Cheshire, CW4 8AA, United Kingdom
Tel: + 44 1477 539 539
Fax: +44 1477 539 540
E-mail:

Copyright © Molecular Profiles

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Chemical interactions between silver nanoparticles and thiols: A comparison of mercaptohexanol again September 30th, 2014

A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014

Iranian Scientists Determine Grain Size, Minimize Time of Nanocomposite Synthesis September 29th, 2014

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

Nanomedicine

A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014

How things coil: Researchers discover that simulation technology designed for Hollywood can be used as a predictive tool for understanding fundamental engineering problems September 29th, 2014

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

Teijin Aramid’s carbon nanotube fibers awarded with Paul Schlack prize: New generation super fibers bring wave of innovations to fiber market September 25th, 2014

Announcements

Chemical interactions between silver nanoparticles and thiols: A comparison of mercaptohexanol again September 30th, 2014

A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014

Iranian Scientists Determine Grain Size, Minimize Time of Nanocomposite Synthesis September 29th, 2014

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014

Teijin Aramid’s carbon nanotube fibers awarded with Paul Schlack prize: New generation super fibers bring wave of innovations to fiber market September 25th, 2014

New chip promising for tumor-targeting research September 22nd, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE